Cessatech AS (XSAT:CESSA) Other Current Liabilities: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CESSA Cessatech AS XSAT:CESSA
28 GF Score
Price kr10.40
! 2 Warning Signs
View Full Analysis

What is Cessatech AS Other Current Liabilities?

Cessatech AS XSAT:CESSA +3.48% 28 Other Current Liabilities is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:CESSA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Cessatech AS's other current liabilities for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Cessatech AS's quarterly other current liabilities declined from Sep. 2025 (kr1.24 Mil) to Dec. 2025 (kr0.00 Mil) but then from Dec. 2025 (kr0.00 Mil) to Mar. 2026 (kr0.00 Mil).

Cessatech AS's annual other current liabilities declined from Dec. 2023 (kr8.64 Mil) to Dec. 2024 (kr4.97 Mil) and declined from Dec. 2024 (kr4.97 Mil) to Dec. 2025 (kr0.00 Mil).

Cessatech AS Other Current Liabilities Related Terms

Cessatech AS Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Cessatech AS's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cessatech AS Other Current Liabilities Chart

Cessatech AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 0.00 0.62 8.64 4.97 0.00

Cessatech AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.73 2.49 1.24 0.00 0.00
XSAT:CESSA
28GF Score
Cessatech AS XSAT:CESSA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cessatech AS Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of kr0.00 Mil mean?
Cessatech AS (XSAT:CESSA) has a Other Current Liabilities of kr0.00 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Cessatech AS.
Is Cessatech AS's Other Current Liabilities too high?
Cessatech AS's current Other Current Liabilities is kr0.00 Mil. Overall, Cessatech AS has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's Other Current Liabilities compare to VRTX and REGN?
Cessatech AS's Other Current Liabilities of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Cessatech AS. Cessatech AS's current Other Current Liabilities is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (XSAT:CESSA) has a current Other Current Liabilities of kr0.00 Mil. The current Other Current Liabilities is kr0.00 Mil. Cessatech AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Cessatech AS (XSAT:CESSA), the current Other Current Liabilities is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cessatech AS Business Description

Other Exchanges 8GN:Germany
Address Strandvejen 60, Hellerup, DNK, DK- 2900
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
28GF Score

Get the complete analysis for XSAT:CESSA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.40
Price